![louisiana glp-1 stomach paralysis class action Ozempic Lawsuit [July 2026 Update] Ozempic Lawsuit [July 2026 Update]](https://www.torhoermanlaw.com/wp-content/uploads/2024/05/Damages-in-Ozempic-Lawsuits.jpg)
louisiana glp-1 stomach paralysis class action Ozempic Lawsuit [July 2026 Update] Ozempic Lawsuit [July 2026 Update]
Description
Whether that improves health is unclear.
As of early 2026, several potent single, dual, and triple incretin receptor agonists are in Phase 2/3 trials for MASH including : Survodutide : A dual glucagon (GCGR)/GLP-1 receptor agonist that has shown significant MASH resolution in Phase 2 trials
![louisiana glp-1 stomach paralysis class action Ozempic Lawsuit [July 2026 Update] Ozempic Lawsuit [July 2026 Update]](https://www.bursor.com/wp-content/uploads/iStock-2155518034-scaled-e1741638529576.jpg)
Safety screening layer (contraindications screen + red flag symptom screen with structured notes fields)
![louisiana glp-1 stomach paralysis class action Ozempic Lawsuit [July 2026 Update] Ozempic Lawsuit [July 2026 Update]](https://images.axios.com/mMaDeJmZBy82ABUjZ_CP0emIkjI=/0x0:1600x900/1920x1080/2025/08/11/1754930562022.png)
Explore savings options, including the Wegovy Savings Card, to make your treatment more affordable
![louisiana glp-1 stomach paralysis class action Ozempic Lawsuit [July 2026 Update] Ozempic Lawsuit [July 2026 Update]](https://www.seegerweiss.com/wp-content/uploads/2023/10/AdobeStock_501320442-1-scaled.jpeg)
Some even suggest that GLP-1 agonists might have the potential to supplant MASH therapy in its entirety
![louisiana glp-1 stomach paralysis class action Ozempic Lawsuit [July 2026 Update] Ozempic Lawsuit [July 2026 Update]](https://www.atraxialaw.com/uploads/ozempic-mounjaro-cause-gastroparesis-what-know.jpg?w=550&q=70&zc=1)
